Patients with multiple myeloma, especially those treated with anti-CD38 mAbs, are considered high risk for breakthrough COVID-19 due to suboptimal antibody response following vaccination and underlying immune deficiency from the disease itself [10, 11]. This evidence concerns the gene CD38 and AL amyloidosis.